ARC-omix combines polygenic risk scores with rare-variants and family history on the Blended Genome-Exome pipeline — amortizing validation across every module and issuing consistent, guideline-anchored reports.
Layer 01
Ensemble PRSMix scores for each condition, ancestry-calibrated on genotype-derived principal components. This is the sole risk layer for the ARC-PREVENT prevention panel and the anchor of every ARC indication test.
Layer 02
Variant classification follows the gene-specific ACMG/AMP rules issued by the ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel, co-chaired by our founder, with independent two-reviewer sign-out.
Layer 03
Structured family history is collected at ordering and modeled as an independent multiplier on baseline risk, alongside polygenic and monogenic signals.
Layer 04
A targeted plasma panel to complement genomic risk assessment in a later release.
We model polygenic burden, rare variants, and family history as independent multipliers on a baseline hazard — the Pooled Cohort Equations for coronary heart disease, and the analogous clinical data algorithm for other modules. Combining partially non-overlapping signals leads to reclassification near the action threshold.
01
Saliva or blood draw from any partnered laboratory; family history captured via secure portal.
02
Blended Genome-Exome sequencing performed by our partner lab.
03
Polygenic, monogenic, and family-history results scored and combined in a single version-locked pipeline.
04
A single report delivered to the ordering clinician, with EHR-embedded clinical decision support and cascade-testing prompts on monogenic-positive findings.
Pilot programs available for academic medical centers and integrated health systems.